靶向胞内转录因子BOB1的TCR疗法用于多发性骨髓瘤及其他B细胞恶性肿瘤
研究分离出靶向HLA-B*07:02提呈的胞内B细胞特异性转录因子BOB1肽段的TCR,通过TCR基因转移使受体T细胞获得BOB1特异性。TCR转导T细胞在体外有效裂解原代B细胞白血病、套细胞淋巴瘤和多发性骨髓瘤细胞,并识别健康BOB1表达B细胞;在已建立多发性骨髓瘤的异种移植小鼠模型中观察到明确体内抗肿瘤反应,且对广谱BOB1阳性但HLA-B*07:02阳性的非造血和造血细胞无反应性,提示无脱靶毒性。作者认为BOB1特异性TCR工程T细胞可能为B细胞恶性肿瘤患者提供新的细胞治疗选择。
要点
- 分离出靶向HLA-B*07:02提呈的BOB1肽段的TCR,基因转移后使T细胞获得BOB1特异性。
- TCR转导T细胞体外有效裂解原代B细胞白血病、套细胞淋巴瘤和多发性骨髓瘤细胞。
- 异种移植小鼠模型中BOB1特异性TCR工程T细胞显示明确体内抗肿瘤反应。
核心结论
- 作者认为,给予BOB1特异性TCR工程T细胞可能为包括多发性骨髓瘤在内的B细胞恶性肿瘤患者提供新的细胞治疗选择。
研究设计与样本
- 研究分离靶向HLA-B*07:02提呈的胞内B细胞特异性转录因子BOB1肽段的TCR,并通过TCR基因转移将BOB1特异性导入受体T细胞。
- 体外评估TCR转导T细胞对原代B细胞白血病、套细胞淋巴瘤和多发性骨髓瘤的裂解活性及对健康BOB1表达B细胞的识别。
- 在已建立多发性骨髓瘤的异种移植小鼠模型中评估BOB1特异性TCR工程T细胞的体内抗肿瘤反应。
主要发现
- TCR转导T细胞在体外有效裂解原代B细胞白血病、套细胞淋巴瘤和多发性骨髓瘤细胞。
- 观察到TCR转导T细胞对健康BOB1表达B细胞的识别和裂解。
- TCR修饰T细胞在遇到抗原时表现出强烈的BOB1特异性增殖。
- 在已建立多发性骨髓瘤的异种移植小鼠模型中,BOB1特异性TCR工程T细胞显示明确的体内抗肿瘤反应。
- 对广谱BOB1阳性但HLA-B*07:02阳性的非造血和造血细胞无反应性,提示无脱靶毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy for hematological malignancies or solid tumors by administration of monoclonal antibodies or T cells engineered to express chimeric antigen receptors or T-cell receptors (TCRs) has demonstrated clinical efficacy. However, antigen-loss tumor escape variants and the absence of currently targeted antigens on several malignancies hamper the widespread application of immunotherapy. We have isolated a TCR targeting a peptide of the intracellular B cell-specific transcription factor BOB1 presented in the context of HLA-B*07:02. TCR gene transfer installed BOB1 specificity and reactivity onto recipient T cells. TCR-transduced T cells efficiently lysed primary B-cell leukemia, mantle cell lymphoma, and multiple myeloma in vitro. We also observed recognition and lysis of healthy BOB1-expressing B cells. In addition, strong BOB1-specific proliferation could be demonstrated for TCR-modified T cells upon antigen encounter. Furthermore, clear in vivo antitumor reactivity was observed of BOB1-specific TCR-engineered T cells in a xenograft mouse model of established multiple myeloma. Absence of reactivity toward a broad panel of BOB1- but HLA-B*07:02+ nonhematopoietic and hematopoietic cells indicated no off-target toxicity. Therefore, administration of BOB1-specific TCR-engineered T cells may provide novel cellular treatment options to patients with B-cell malignancies, including multiple myeloma.
引用
- Jahn L, Hombrink P, Hagedoorn RS, et al. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood. 2017. PMID: 28053195. doi:10.1182/blood-2016-09-737536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。